FDA-Approved GLP-1 Drugs for Weight Loss

Last reviewed: June 7, 2026

Last updated: June 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Three GLP-1 drugs currently carry FDA approval for weight loss: semaglutide, tirzepatide, and liraglutide. Since 2021, these medications have transformed obesity care by helping patients lose 15–22% of body weight through appetite regulation and improved blood sugar control. PlexusDx compounds pharmaceutical-grade versions of these agents in licensed 503A pharmacies, making them accessible across all 50 states without insurance.

FDA-Approved GLP-1 Medications for Obesity Treatment

Semaglutide received FDA approval for chronic weight management in 2021 and is marketed as Wegovy for weight loss and Ozempic for type 2 diabetes. Tirzepatide, a dual GLP-1 and GIP receptor agonist, earned FDA approval for obesity in 2023 and is sold as Zepbound for weight loss and Mounjaro for diabetes. Liraglutide, approved in 2014 as Saxenda, was the first GLP-1 drug cleared specifically for weight loss but typically produces smaller weight reductions than newer agents. All three work by slowing stomach emptying, reducing hunger signals, and increasing satiety.

Clinical trials demonstrate that semaglutide at maximum dose produces average weight loss of 15–17%, while tirzepatide achieves 20–22% loss in recent SUMO trials. Both drugs improve cardiovascular outcomes and blood pressure in patients with obesity and type 2 diabetes. The choice between them depends on individual metabolic factors, injectable preference, and treatment goals—reasons why PlexusDx offers both as compounded options starting at $149/mo for semaglutide injection and $249/mo for tirzepatide injection.

Compounded vs. Brand-Name GLP-1 Drugs: Key Differences

Brand-name Wegovy and Zepbound are FDA-approved finished products, while PlexusDx compounds semaglutide and tirzepatide in licensed 503A pharmacies under strict pharmaceutical standards. Compounded medications contain the same active pharmaceutical ingredients and follow the same quality-control protocols as brands, but cost significantly less—PlexusDx semaglutide injection starts at $149/mo compared to $1,350+ for Wegovy. No insurance approval, prior authorization, or waiting lists apply; PlexusDx ships within days to all 50 states.

A key distinction: PlexusDx does not market compounded drugs as FDA-approved products, because compounding occurs after FDA-approved drug ingredients are obtained. However, all PlexusDx formulations are prepared by licensed 503A compounding pharmacies (never 503B), ensuring pharmaceutical-grade purity and sterility. HSA and FSA funds cover PlexusDx medications, reducing out-of-pocket costs further for eligible patients.

Newer GLP-1 Options: Dual-Compound and Oral Formulations

Beyond single-agent semaglutide or tirzepatide, PlexusDx offers GLP-Squared—a proprietary dual-compound injection combining semaglutide and tirzepatide in one formulation. This approach allows clinicians to target multiple peptide pathways simultaneously, potentially enhancing weight loss and metabolic improvement in patients who plateau on monotherapy. GLP-Squared Injection starts at $249/mo, and GLP-Squared Oral starts at $369/mo for patients who prefer tablets over injections.

Oral formulations of semaglutide and tirzepatide are also available through PlexusDx at $249/mo and $279/mo respectively. While oral GLP-1s are less bioavailable than injectables (requiring higher doses and fasting protocols), they appeal to needle-averse patients. PlexusDx also offers a Microdose GLP-1 Protocol at $129/mo for those seeking milder appetite suppression or testing tolerance before standard dosing.

Personalized GLP-1 Selection With Precision Peptide Genetic Testing

Not all patients respond equally to semaglutide or tirzepatide, and individual genetic variation in peptide-pathway genes explains much of this difference. PlexusDx Precision Peptide Genetic Test ($99 add-on after first treatment month) analyzes 14 metabolic pathways and 49 peptides—including key variants in GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)—to predict which GLP-1 formulation and dose level will work best for your body.

Patients with favorable GLP1R variants typically show strong semaglutide response, while those with enhanced GIPR signaling may benefit more from tirzepatide's dual-agonist action. The Precision Peptide test generates 150+ genetic insights that PlexusDx clinicians use to customize your therapy, ensuring you receive the right medication at the right dose from the start. Testing is optional but highly recommended for patients with prior weight-loss medication failures or slower-than-expected progress.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the difference between Wegovy, Ozempic, and compounded semaglutide?

Wegovy and Ozempic are FDA-approved brand products containing semaglutide; Ozempic is dosed for diabetes, Wegovy for weight loss. PlexusDx compounded semaglutide contains the same active ingredient prepared in licensed 503A pharmacies at a lower cost ($149/mo) without insurance requirements. Both are pharmaceutical-grade and equally safe when prescribed by a clinician.

Which GLP-1 drug produces the most weight loss?

Tirzepatide produces the greatest average weight loss (20–22%) in clinical trials, followed by semaglutide (15–17%), then liraglutide (5–10%). However, individual response varies based on genetics, adherence, and lifestyle. PlexusDx Precision Peptide Genetic Test can predict your likely response to each drug before starting treatment.

Do I need insurance to afford GLP-1 treatment at PlexusDx?

No. PlexusDx serves all 50 states with no insurance required, no membership fees, and no prior authorization delays. HSA and FSA funds are accepted. Compounded semaglutide injection starts at $149/mo and tirzepatide injection at $249/mo, substantially lower than brand-name out-of-pocket costs.

Are compounded GLP-1 drugs from PlexusDx safe?

Yes. All PlexusDx formulations are prepared in licensed 503A compounding pharmacies under FDA-regulated pharmaceutical standards. Compounded drugs are not FDA-approved finished products, but the ingredient sources are FDA-approved, and compounding follows strict sterility and potency protocols. Your PlexusDx clinician monitors safety through ongoing check-ins.

What does the Precision Peptide Genetic Test tell me about my GLP-1 response?

The test analyzes genetic variants in GLP1R, GIPR, FTO, MC4R, and 10 other metabolic pathways to predict which GLP-1 drug you will respond to best, your likely weight-loss range, and whether you may experience increased or reduced appetite suppression. Results guide PlexusDx clinicians to choose semaglutide, tirzepatide, or GLP-Squared and estimate your target dose and timeline.

Which GLP-1 Drugs Are Approved for Obesity?